Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15M Buy
623,853
+54,153
+10% +$1.42M 0.34% 57
2026
Q1
$16M Buy
569,700
+19,329
+4% +$515K 0.44% 45
2025
Q4
$13.7M Buy
550,371
+40,920
+8% +$1.03M 0.35% 53
2025
Q3
$13M Buy
509,451
+89,822
+21% +$2.22M 0.33% 60
2025
Q2
$10.2M Buy
419,629
+54,578
+15% +$1.27M 0.29% 61
2025
Q1
$9.25M Buy
365,051
+73,670
+25% +$1.93M 0.31% 60
2024
Q4
$7.73M Buy
+291,381
New +$7.9M 0.24% 65

Other funds holding PFE

SBI Securities's PFE Position: Q2 2026 in Review

SBI Securities increased its Pfizer (PFE) stake by 9.5% in Q2 2026, buying an estimated $1.42M and bringing the position to 623,853 shares worth $15M. The position accounts for 0.34% of the portfolio, ranked #57.

SBI Securities first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. The position peaked at $16M in Q1 2026. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • SBI Securities held 623,853 shares of Pfizer worth $15M as of Q2 2026.
  • SBI Securities bought 54,153 Pfizer shares in Q2 2026, an estimated $1.42M.
  • Pfizer made up 0.34% of SBI Securities's portfolio in Q2 2026, its #57 holding.
  • SBI Securities first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Pfizer position peaked at $16M in Q1 2026.
  • 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.